<DOC>
	<DOCNO>NCT02796170</DOCNO>
	<brief_summary>To assess effect SGLT-2 inhibitor blood pressure urinary angiotensinogen . This cross study design , 40 subject receive Dapagliflozin 6 week follow placebo 6 week , placebo 6 week follow Dapagliflozin 6 week . In addition arm 10 subject receive sulfonylurea open label comparative cross subject assess effect Dapagliflozin may also part due improve glycemic control .</brief_summary>
	<brief_title>Inhibition Urinary Angiotensinogen Reduction Blood Pressure SGLT2 Inhibition Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Clinical trial two SGLT2 inhibitor , canagliflozin dapagliflozin , report drop systolic blood pressure ~5 mmHg . Inappropriate activation intrarenal renin-angiotensin system ( RAS ) major contributor increase arterial pressure tissue injury include diabetic nephropathy . A key factor intrarenal RAS activation stimulation intrarenal angiotensinogen ( AGT ) precursor angiotensin peptide . From previous study , show high blood sugar patient type1 type 2 diabetes mellitus accompany elevate intrarenal AGT urinary AGT level . High glucose result stimulation AGT production . The high glucose level augments intrarenal AGT level diabetes mellitus leading development high blood pressure diabetic nephropathy . The investigator propose conduct single-center randomize , double blind , cross study effect Dapagliflozin 6 week , follow placebo 6 week treatment allocation ( get placebo first cross Dapagliflozin vice versa ) . Treatment stratify accord underlie presence absence hypertension . 1 . Type 2 diabetes hypertension RAAS block drug stable blood pressure therapy ; n= 20 2 . Type 2 diabetes without hypertension RAAS block drug n=10 If unable recruit 10 participant without hypertension investigator increase number hypertension total 30 . Stratification hypertension status remain important understanding effect SGLT2 inhibition patient BP lower drug . In addition Sulfonylurea ( SU ) arm also include - 10 participant metformin background therapy ( exclusion SGLT-2 inhibitor sulfonylurea ) recruit . This open-labeled arm . Participants assess baseline . Participants receive usual care 6 week . At end 6 week , participant undergo another assessment provide SU 6 week . At end 6 week , participant undergo assessment . The aim determine whether effect see Dapagliflozin specific drug relate simply improved glycemic control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<criteria>Type 2 diabetes hypertension RAAS block drug OR Type 2 diabetes without hypertension RAAS block drug Hemoglobin A1c 7 % 9 % ( inclusive ) Estimated glomerular filtration rate ( eGFR ) ≥60 ml/min Capacity understand sign inform consent Severe hepatic insufficiency and/or significant abnormal liver function define AST and/or ALT &gt; 3x ULN Total bilirubin &gt; 2.0 mg/dL Positive serologic evidence current infectious liver disease , include Hepatitis B viral antibody IGM , Hepatitis B surface antigen , Hepatitis C virus antibody Estimated glomerular filtration rate ( eGFR ) &lt; 60 ml/min Recent cardiovascular event last 2 month : acute coronary syndrome ( ACS ) , hospitalization unstable angina acute myocardial infarction , acute stroke TIA , post coronary artery revascularization Congestive Heart Failure define New York Heart Association ( NYHA ) class IV , unstable acute congestive heart failure Pregnant breastfeeding patient Patients , judgement investigator , may risk dehydration Blood pressure enrollment : Systolic ≥165 mmHg and/or Diastolic ≥110 mmHg ; At randomization : Systolic ≥160 mmHg and/or Diastolic ≥100 mmHg Use SGLT2 inhibitor class drug exclusion patient . For patient sulfonylurea arm , use sulfonylurea class drug exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>SGLT-2 inhibitor</keyword>
	<keyword>urinary angiotensinogen</keyword>
</DOC>